Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Amrubicin

Small molecule · Inhibitor of topoisomerase II (TOP2A) · developed by AbbVie

Phase 3 Most advanced trial
ABBV Developer
1 Registered trials

What is Amrubicin?

Amrubicin is a synthetic anthracycline that intercalates into DNA and inhibits topoisomerase II, leading to inhibition of DNA replication and protein synthesis, followed by cell death. It is studied in small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
topoisomerase II (TOP2A)
Mechanism
Inhibitor of topoisomerase II (TOP2A)
Pathways
DNA replication inhibition, apoptosis
Therapy area
Oncology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
93N13LB4Z2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07365241 Phase 3 Small Cell Lung Cancer Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Small Cell Lung Cancer

Other drugs acting on TOP2A

Doxorubicin FDA approved Berubicin Phase 2 Camsirubicin Phase 1 IMX-110 Phase 1/2 Pegylated Liposomal Doxorubicin Phase 3

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Amrubicin

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.